DIR Return Create A Forum - Home
---------------------------------------------------------
Road2HardCoreIron
HTML https://road2hardcoreiron.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: INSULIN & HGH GOOD AND BAD
*****************************************************
#Post#: 7163--------------------------------------------------
New Liver Target Insulin
DIR By: Road2HardCoreIron
Date: June 10, 2026, 9:22 am
---------------------------------------------------------
The new liver-targeted insulin therapy is called
Hepatic-Directed Vesicle (HDV) insulin, a breakthrough treatment
designed to mimic how a healthy body naturally processes insulin
to drastically reduce the risk of dangerous blood sugar crashes
(hypoglycemia).Developed by Diasome Pharmaceuticals, this
therapy recently made headlines at the American Diabetes
Association (ADA) 2026 Scientific Sessions for its highly
successful Phase 2b clinical trial results.How HDV-Insulin
WorksStandard injected insulin goes straight into the general
bloodstream, which often causes the muscles and fat cells to
absorb too much sugar, leaving the brain starving for fuel and
leading to dangerous drops. HDV solves this by shifting the
focus back to the liver:The Molecular "Tag": HDV technology adds
a tiny, microscopic tag (a phospholipid matrix with biotin) to
standard short-acting insulin.Liver Priority: Because the liver
contains the body’s highest concentration of biotin receptors,
it acts like a magnet, drawing the insulin straight to liver
cells.Mimicking Nature: This mimics the natural pathway of
insulin released by a healthy pancreas, which goes directly to
the liver via the portal vein.Why It Prevents Dangerous Blood
Sugar DropsThe biggest medical breakthrough of HDV-insulin is
its unique ability to safely store and release sugar.Building a
Sugar Reserve: When you take HDV-insulin at mealtime, it signals
the liver to absorb glucose and safely store it as
glycogen.Automatic Rescue: If your blood sugar begins to crash
later, the liver automatically breaks down that stored glycogen
and releases glucose back into the bloodstream.Zero Severe
Crashes: In a prominent six-month clinical trial (the OPTI-2
trial) consisting of 226 patients, not a single patient on
HDV-insulin experienced a severe hypoglycemic event, compared to
multiple patients on standard insulin.Key Clinical Trial
OutcomesData from the clinical trials show that HDV-insulin
successfully eliminates the historical "trade-off" where
patients had to risk dangerous lows just to get tight blood
sugar control.Same Control, Fewer Lows: Patients achieved the
exact same long-term A1C blood sugar control as standard
insulin, but with significantly fewer total drops.Fewer
Nighttime Crashes: The therapy demonstrated a massive 21% to 43%
reduction in nighttime level 2 hypoglycemic events (where blood
sugar drops below 54 mg/dL).Overcoming Past Failures: Unlike
previous liver-targeted attempts by other pharmaceutical
companies that were halted due to elevated liver enzymes, HDV
has proven safe for the liver in its trials.What's Next?While
this is a monumental shift for Type 1 diabetes care, the therapy
is currently preparing for Phase 3 clinical trials, which are
the final step before seeking full FDA approval and widespread
commercial release.If you are following diabetes tech and
treatment developments, would you like to know more about the
timeline for the upcoming Phase 3 trials, or are you interested
in other emerging "smart insulins" that are currently in
development?
*****************************************************
Page 1 of 1